Pfizer Inc. (NYSE:PFE) was the target of a significant drop in short interest in October. As of October 31st, there was short interest totalling 51,408,403 shares, a drop of 11.9% from the October 13th total of 58,325,639 shares. Based on an average daily trading volume, of 17,276,742 shares, the days-to-cover ratio is presently 3.0 days. Approximately 0.9% of the shares of the stock are sold short.
In other news, EVP Alexander R. Mackenzie sold 7,350 shares of Pfizer stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $35.65, for a total transaction of $262,027.50. Following the sale, the executive vice president now directly owns 117,432 shares of the company’s stock, valued at $4,186,450.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Sally Susman sold 38,230 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total value of $1,338,050.00. Following the transaction, the insider now owns 145,649 shares of the company’s stock, valued at $5,097,715. The disclosure for this sale can be found here. Insiders sold 60,280 shares of company stock worth $2,118,988 over the last ninety days. 0.06% of the stock is currently owned by insiders.
Several large investors have recently added to or reduced their stakes in the stock. Altfest L J & Co. Inc. boosted its holdings in shares of Pfizer by 67.0% in the 2nd quarter. Altfest L J & Co. Inc. now owns 107,278 shares of the biopharmaceutical company’s stock worth $3,603,000 after purchasing an additional 43,024 shares in the last quarter. HL Financial Services LLC boosted its holdings in Pfizer by 1.1% during the 2nd quarter. HL Financial Services LLC now owns 3,222,985 shares of the biopharmaceutical company’s stock valued at $108,260,000 after acquiring an additional 35,744 shares during the period. Sphera Funds Management LTD. purchased a new stake in Pfizer during the 1st quarter valued at about $13,342,000. Searle & CO. boosted its holdings in Pfizer by 92.7% during the 1st quarter. Searle & CO. now owns 80,052 shares of the biopharmaceutical company’s stock valued at $2,739,000 after acquiring an additional 38,500 shares during the period. Finally, Hartford Financial Management Inc. boosted its holdings in Pfizer by 10.8% during the 2nd quarter. Hartford Financial Management Inc. now owns 8,538 shares of the biopharmaceutical company’s stock valued at $286,000 after acquiring an additional 835 shares during the period. Institutional investors own 69.89% of the company’s stock.
A number of brokerages have recently issued reports on PFE. Deutsche Bank set a $38.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Wednesday, October 11th. BMO Capital Markets set a $37.00 target price on Pfizer and gave the stock a “buy” rating in a report on Tuesday, October 10th. Barclays set a $38.00 target price on Pfizer and gave the stock a “buy” rating in a report on Wednesday, October 11th. Zacks Investment Research downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Finally, Jefferies Group set a $38.00 price objective on Pfizer and gave the company a “neutral” rating in a research note on Monday, October 16th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $38.66.
Shares of Pfizer (PFE) traded down $0.43 on Tuesday, hitting $35.63. The company’s stock had a trading volume of 22,320,565 shares, compared to its average volume of 19,989,418. The company has a market capitalization of $216,671.69, a price-to-earnings ratio of 14.54, a PEG ratio of 2.57 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. Pfizer has a 52-week low of $30.51 and a 52-week high of $36.78.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The firm had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. During the same period in the previous year, the company posted $0.61 earnings per share. The business’s revenue was up .9% on a year-over-year basis. equities analysts forecast that Pfizer will post 2.59 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, December 1st. Investors of record on Friday, November 10th were paid a dividend of $0.32 per share. The ex-dividend date of this dividend was Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.59%. Pfizer’s payout ratio is 79.01%.
WARNING: This report was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/05/short-interest-in-pfizer-inc-pfe-declines-by-11-9.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.